Sustained attention during prolonged walking in persons with multiple sclerosis

Introduction: Accelerated early CGMV loss occurs in interferon-treated RMS patients. Methods: CGMV was quantified in randomized phase 3 (SUNBEAM-NCT02294058, RADIANCE-NCT02047734) trials comparing oral ozanimod 0.92 and 0.46mg/day with intramuscular interferon 30μg/ week and an ongoing, open-label extension trial (DAYBREAK-NCT02576717) of ozanimod 0.92mg/day in RMS. MRI was performed at months 6 (SUNBEAM), 12 (RADIANCE/SUNBEAM), and 24 (RADIANCE), then every 12 months (DAYBREAK). CGMV was analyzed through DAYBREAK month 36. Results: The rate of CGMV loss was greater (P<0.001) with inter-feron than ozanimod 0.92mg during SUNBEAM/RADIANCE: LS mean percentage change from baseline was-0.67% vs-0.02%, respectively, at month 6 and-1.04% vs-0.16% at month 12 in SUNBEAM, and-0.80% vs-0.13% at month 12 and-1.26% vs-0.53% at month 24 in RADIANCE. Switching from interferon to ozanimod reversed CGMV loss in year 1 of DAYBREAK. Thereafter, annualized rates of CGMV loss were similar among participants who switched from interferon and those continuously treated with ozanimod. Patients continuously treated with ozani-mod lost less CGMV in DAYBREAK relative to RADIANCE/ SUNBEAM baseline than patients initially treated with interferon. Conclusion: Switching from interferon to ozanimod reversed CGMV loss. Earlier treatment with ozanimod led to less CGMV loss over 4-5 years, supporting early ozanimod use. This abstract has been previously presented at AAN 2022

Publication year:2022

Accessibility:Open